Annexon, Inc. ANNX
Set alert
4.05 USD +0.04 +1.00%
At close · Oct 30
4.13 +0.08 +1.98%
After hours · Oct 30, 5:58 PM ET
3.87 Day range 4.09
2.68 52-week range 6.96
- YTD
- -19.32%
- 1 year
- +38.23%
- Open
- 4.00
- Prev close
- 4.01
- Mkt cap
- 767.80M
- Vol
- 2.84M
- Avg vol
- 3.14M
- EPS
- -1.13
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.87
- High
- 4.09
- Forward P/E
- -6.48
- Beta
- 1.15
- Short ratio
- 6.15
- Inst. own
- 92.44%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 5.52
- 200-d avg
- 4.10
- 1y target
- 13.71
5D chart
Signals (45)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 11:15 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:20 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 2 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:55 AM | 3 days ago |
| RSI: Overbought | Oct 28, 10:45 AM | 3 days ago |
| RSI: Overbought | Oct 28, 9:35 AM | 3 days ago |
| RSI: Overbought | Oct 27, 3:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:40 PM | 4 days ago |
| RSI: Oversold | Oct 27, 2:20 PM | 4 days ago |
| RSI: Oversold | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:20 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:00 PM | 5 days ago |
| RSI: Oversold | Oct 26, 3:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:30 PM | 5 days ago |
| RSI: Oversold | Oct 26, 2:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 12:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 5 days ago |
| RSI: Overbought | Oct 26, 10:15 AM | 5 days ago |
| RSI: Overbought | Oct 26, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 23, 3:40 PM | 1 week ago |
| SMA: Bearish | Oct 23, 3:10 PM | 1 week ago |
| SMA: Bearish | Oct 23, 3:00 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 2:40 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 1:40 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:30 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:20 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:15 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:15 PM | 1 week ago |
| SMA: Bearish | Oct 23, 11:55 AM | 1 week ago |
Key statistics
- Market cap
- 994.94M
- Enterprise value
- 819.71M
- Trailing P/E
- 0.00
- Forward P/E
- -6.48
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.38
- EPS (TTM)
- -1.34
- Beta
- 1.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -104.48M
- Total cash
- 238.34M
- Total debt
- 26.20M
- Return on equity
- -81.90%
- Shares outstanding
- 160.47M
- Short % of float
- 13.45%
- 50-day average
- 5.52
- 200-day average
- 4.10
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 13.71 +238.6% upside
Now 4.05
- Target (low)
- 8.00
- Target (mean)
- 13.71
- Target (high)
- 27.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy2
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.30268.
Financials — quick view
ANNX Revenue — quarterly 0
ANNX Net income — quarterly -55.35M
ANNX EPS — quarterly -0.28
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.26 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.23884 | -0.28 | -0.04 | -17.23% |
| May 7, 2026 | Mar 31, 2026 | -0.30 | -0.23 | +0.07 | +23.33% |
| Mar 30, 2026 | Dec 31, 2025 | -0.32 | -0.28 | +0.04 | +12.50% |
| Nov 10, 2025 | Sep 30, 2025 | -0.34 | -0.37 | -0.03 | -8.82% |
| Aug 14, 2025 | Jun 30, 2025 | -0.36 | -0.34 | +0.02 | +5.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 20, 2026 | Chardan Capital | main | Buy | Buy |
| Dec 23, 2025 | Chardan Capital | init | — | Buy |
| Dec 2, 2025 | Clear Street | init | — | Buy |
| Nov 19, 2025 | Wells Fargo | main | Overweight | Overweight |
| Aug 15, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2025 | HC Wainwright & Co. | main | Buy | Buy |
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- annexonbio.com
News
- Annexon To Highlight Phase 3 ARCHER II Clinical Trial Program At Virtual Investor Event
- Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
- Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday
- HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
Your note
Sign in to keep a note on ANNX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARTIS DEAN RICHARD PH.D. | Officer | Sale | Mar 1, 2026 | 180,093 |
| CARSON WILLIAM H. | Director | Purchase | Apr 9, 2026 | 70,405 |
| CHOI JUNG E. | Director | Purchase | Nov 30, 2025 | 0 |
| DANANBERG JAMIE | Officer | Sale | Mar 1, 2026 | 123,582 |
| LEW JENNIFER | Chief Financial Officer | Sale | Mar 1, 2026 | 170,700 |
| LOVE DOUGLAS ESQ. | Chief Executive Officer | Sale | Feb 12, 2025 | 351,554 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 6.29% | 10,222,470 | 63.38M | Dec 30, 2025 |
| Redmile Group, LLC | 6.18% | 10,050,644 | 62.31M | Dec 30, 2025 |
| BVF Inc. | 5.62% | 9,128,080 | 56.59M | Dec 30, 2025 |
| Blackrock Inc. | 5.51% | 8,960,434 | 55.55M | Dec 30, 2025 |
| Vanguard Group Inc | 4.77% | 7,753,387 | 48.07M | Dec 30, 2025 |
| Adage Capital Partners GP L.L.C. | 3.38% | 5,500,000 | 34.10M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2.91% | 4,733,596 | 29.35M | Feb 27, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.65% | 4,314,036 | 26.75M | Dec 30, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 1.49% | 2,422,177 | 15.02M | Feb 27, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.45% | 2,357,790 | 14.62M | Feb 27, 2026 |
| Columbia Acorn Trust-Columbia Acorn Fund | 1.10% | 1,786,958 | 11.08M | Dec 30, 2025 |
| College Retirement Equities Fd.-College Retirement Equities Fd. - Tota | 0.92% | 1,499,900 | 9.30M | Dec 30, 2025 |